Advertisement
UK markets close in 6 hours 29 minutes

  • FTSE 100

    8,107.47
    +28.61 (+0.35%)
     

  • FTSE 250

    19,811.57
    +209.59 (+1.07%)
     

  • AIM

    755.94
    +2.82 (+0.37%)
     

  • GBP/EUR

    1.1660
    +0.0004 (+0.03%)
     

  • GBP/USD

    1.2524
    +0.0013 (+0.10%)
     

  • Bitcoin GBP

    51,427.20
    +394.13 (+0.77%)
     

  • CMC Crypto 200

    1,390.03
    -6.50 (-0.47%)
     

  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     

  • DOW

    38,085.80
    -375.12 (-0.98%)
     

  • CRUDE OIL

    83.74
    +0.17 (+0.20%)
     

  • GOLD FUTURES

    2,360.10
    +17.60 (+0.75%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • HANG SENG

    17,651.15
    +366.61 (+2.12%)
     

  • DAX

    18,055.32
    +138.04 (+0.77%)
     

  • CAC 40

    8,043.76
    +27.11 (+0.34%)
     
PROPERTY:

9 luxury homes to consider if money is no object

Ever thought about what a multimillion pound budget would buy you?

CRISPR Therapeutics to Participate in the 43rd Annual Cowen Health Care Conference

CRISPR Therapeutics AG
Updated ·1-min read
CRISPR Therapeutics AG
CRISPR Therapeutics AG

ZUG, Switzerland and BOSTON, Feb. 27, 2023 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in a fireside chat at 43rd Annual Cowen Health Care Conference on Monday, March 6, 2023, at 10:30 a.m. ET.

A live webcast of the fireside chat will be available on the "Events & Presentations" page in the Investors section of the Company's website at http://ir.crisprtx.com/events. A replay of the webcast will be archived on the Company's website for 14 days following the presentation.

About CRISPR Therapeutics

CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic partnerships with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Boston, Massachusetts and San Francisco, California, and business offices in London, United Kingdom. For more information, please visit www.crisprtx.com.

Investor Contact:
Susan Kim
+1-617-307-7503
susan.kim@crisprtx.com

Media Contact:
Rachel Eides
+1-617-315-4493
rachel.eides@crisprtx.com